Association Between Acquired Bilateral Nevus of Ota-Like Macules Patients' Clinical Characteristics and Melasma Induction/Exacerbation After Q-Switched Laser: A Decadal Comparative Study of 2675 Chinese Women in Two Different Periods.
Ying Li, Ziyang Huang, Yiran Peng, Yingxue Huang, Wei Shi, Ben Wang, Yaling Wang, Dan Jian
{"title":"Association Between Acquired Bilateral Nevus of Ota-Like Macules Patients' Clinical Characteristics and Melasma Induction/Exacerbation After Q-Switched Laser: A Decadal Comparative Study of 2675 Chinese Women in Two Different Periods.","authors":"Ying Li, Ziyang Huang, Yiran Peng, Yingxue Huang, Wei Shi, Ben Wang, Yaling Wang, Dan Jian","doi":"10.1002/lsm.70024","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Post-laser melasma induction/exacerbation remains a critical challenge in treating acquired bilateral nevus of Ota-like macules (ABNOMs). While laser parameters are well-studied, patient-specific risk factors across evolving therapeutic eras require elucidation.</p><p><strong>Methods: </strong>This retrospective cohort analyzed 2675 ABNOMs patients treated with Q-switched lasers in two eras: C1 (2010-2013; 1064 nm-only, n = 1069) and C2 (2020-2023; multi-wavelength, n = 1606). Risk factors were assessed through multivariate logistic regression, incorporating laser wavelength stratification.</p><p><strong>Results: </strong>Era-specific risk reversals emerged: In C1, age > 25, Fitzpatrick IV and patch lesions predicted melasma induction, whereas large/dark lesions showed protective effects. C2 showed inverse risks for lesion characteristics (large/dark lesions showed negative effects), with skin type/age becoming nonsignificant. Despite increased number of patients with pre-existing melasma in C2, melasma exacerbation rates decreased from 87.6% (C1) to 50.1% (C2, p < 0.05) in parallel with diagnostic advances (subclinical melasma detection) and protocol optimization. Wavelength-specific analysis revealed a persistent Fitzpatrick IV risk with 1064 nm versus lesion-driven risks with 694/755 nm. Paradoxically, treatment of dark lesions with 1064 nm reduced the risk of melasma exacerbation, probably through selective melanin targeting.</p><p><strong>Conclusion: </strong>ABNOMs-related melasma risks dynamically evolve with diagnostic/therapeutic advancements, demanding phenotype-specific laser parameter selection. This decade-spanning analysis provides actionable insights for optimizing laser therapy in diverse ABNOMs populations, despite inherent retrospective limitations.</p><p><strong>Clinical trial registration: </strong>Registry and the Registration No. of the study/trial: ChiCTR2500095697.</p>","PeriodicalId":17961,"journal":{"name":"Lasers in Surgery and Medicine","volume":" ","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lasers in Surgery and Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/lsm.70024","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Post-laser melasma induction/exacerbation remains a critical challenge in treating acquired bilateral nevus of Ota-like macules (ABNOMs). While laser parameters are well-studied, patient-specific risk factors across evolving therapeutic eras require elucidation.
Methods: This retrospective cohort analyzed 2675 ABNOMs patients treated with Q-switched lasers in two eras: C1 (2010-2013; 1064 nm-only, n = 1069) and C2 (2020-2023; multi-wavelength, n = 1606). Risk factors were assessed through multivariate logistic regression, incorporating laser wavelength stratification.
Results: Era-specific risk reversals emerged: In C1, age > 25, Fitzpatrick IV and patch lesions predicted melasma induction, whereas large/dark lesions showed protective effects. C2 showed inverse risks for lesion characteristics (large/dark lesions showed negative effects), with skin type/age becoming nonsignificant. Despite increased number of patients with pre-existing melasma in C2, melasma exacerbation rates decreased from 87.6% (C1) to 50.1% (C2, p < 0.05) in parallel with diagnostic advances (subclinical melasma detection) and protocol optimization. Wavelength-specific analysis revealed a persistent Fitzpatrick IV risk with 1064 nm versus lesion-driven risks with 694/755 nm. Paradoxically, treatment of dark lesions with 1064 nm reduced the risk of melasma exacerbation, probably through selective melanin targeting.
Conclusion: ABNOMs-related melasma risks dynamically evolve with diagnostic/therapeutic advancements, demanding phenotype-specific laser parameter selection. This decade-spanning analysis provides actionable insights for optimizing laser therapy in diverse ABNOMs populations, despite inherent retrospective limitations.
Clinical trial registration: Registry and the Registration No. of the study/trial: ChiCTR2500095697.
期刊介绍：
Lasers in Surgery and Medicine publishes the highest quality research and clinical manuscripts in areas relating to the use of lasers in medicine and biology. The journal publishes basic and clinical studies on the therapeutic and diagnostic use of lasers in all the surgical and medical specialties. Contributions regarding clinical trials, new therapeutic techniques or instrumentation, laser biophysics and bioengineering, photobiology and photochemistry, outcomes research, cost-effectiveness, and other aspects of biomedicine are welcome. Using a process of rigorous yet rapid review of submitted manuscripts, findings of high scientific and medical interest are published with a minimum delay.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
